Status:
UNKNOWN
Usability, Immediate, and 30 Day Effect of External Neuromodulation With iTEAR100 Generation 2 in Dry Eye Patients
Lead Sponsor:
Olympic Ophthalmics, Inc.
Conditions:
Dry Eye
Eligibility:
All Genders
21+ years
Phase:
PHASE4
Brief Summary
iTEAR generation 2 will be supplied t eligible subjects at Day 0. At Day 30, symptom questionnaires and ophthalmic exam will be performed.
Detailed Description
TEAR generation 2 will be supplied t eligible subjects at Day 0. At Day 30, symptom questionnaires and ophthalmic exam will be performed. At both exam days, a Schirmer test before and after will be pe...
Eligibility Criteria
Inclusion
- Dry eye
Exclusion
- unable to read consent
- investigator discretion
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05304637
Start Date
March 1 2022
End Date
July 1 2022
Last Update
March 31 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Olympic Ophthalmics
Issaquah, Washington, United States, 98027
2
Periman Eye Institute
Seattle, Washington, United States, 98119